Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03314207 · ClinicalTrials.gov registry record
Clinical Evaluation of Patients With X-linked Retinitis Pigmentosa (XLRP)
A clinical trial, sponsored by Beacon Therapeutics.
- Completed
- Registry status
- 14
- Enrollment target
NCT03314207 is a clinical trial that has completed, run by Beacon Therapeutics. The registered enrollment target is 14 participants.
The verdict
NCT03314207 has completed, sponsored by Beacon Therapeutics.
- COMPLETED
- Registry status
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate subjects with X-linked retinitis pigmentosa caused by RPGR-ORF15 mutations in a clinical setting to fully characterize their condition, measure testing variability, and estimate rates of progression of clinical parameters.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2017-12-01 |
| Est. Completion | 2022-02-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03314207
The ClinicalTrials.gov registry entry for NCT03314207 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beacon Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03314207 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03314207 about?
NCT03314207 is a clinical study titled "Clinical Evaluation of Patients With X-linked Retinitis Pigmentosa (XLRP)". The purpose of this study is to evaluate subjects with X-linked retinitis pigmentosa caused by RPGR-ORF15 mutations in a clinical setting to fully characterize their condition, measure testing variability, and estimate rates of progression of clinical parameters.
What is the current status of trial NCT03314207?
This trial is currently completed. The enrollment target is 14 participants. The study started on 2017-12-01. Estimated completion is 2022-02-10.
Who is sponsoring clinical trial NCT03314207?
This trial is sponsored by Beacon Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.